Histone Deacetylase 10-inhibitor Co-Treatment in Cancer
Histone deacetylase inhibitors (HDACi) are prom-ising anticancer agents and are currently being evaluated in clinical trials. However, due to their unselective action, pan-HDACi exhibit dose-limiting side-effects restricting their full potential in anti-cancer therapy. Therefore, characterization of the molecular function of single HDAC isozymes is of major importance for a targeted therapy with less side-effects.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
“Nanostitches” enable lighter and tougher composite materials
In research that may lead to next-generation airplanes and spacecraft, MIT engineers used carbon nanotubes to prevent cracking in multilayered composites. To save on fuel and reduce aircraft emissions, engineers…
Trash to treasure
Researchers turn metal waste into catalyst for hydrogen. Scientists have found a way to transform metal waste into a highly efficient catalyst to make hydrogen from water, a discovery that…
Real-time detection of infectious disease viruses
… by searching for molecular fingerprinting. A research team consisting of Professor Kyoung-Duck Park and Taeyoung Moon and Huitae Joo, PhD candidates, from the Department of Physics at Pohang University…